CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation VCEL, a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry conferences:
- Nick Colangelo, president and CEO, will present at the Ladenburg 2018 Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 11:30 AM EDT
http://wsw.com/webcast/ladenburg4/vcel/ - Nick Colangelo, president and CEO, will present at the Cantor Global Healthcare Conference in New York, NY on Wednesday, October 3, 2018 at 1:40 PM EDT
http://wsw.com/webcast/cantor7/vcel/ - Dan Orlando, Chief Operating Officer, will present at the Cell & Gene Meeting on the Mesa in La Jolla, CA on, Thursday, October 4, 2018 at 5:15 PM PDT
http://www.meetingonthemesa.com/webcast
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
David.schull@russopartnersllc.com
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
Karen.chase@russopartnersllc.com
Investor Contacts:
Chad Rubin
Solebury Trout
crubin@troutgroup.com
+1 (646) 378-2947
Lee Stern
Solebury Trout
lstern@troutgroup.com
+1 (646) 378-2922
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.